Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety, Pharmacokinetics and Immunomodulatory Effects of AB103, a CD28 Co-stimulatory Receptor Antagonist, in Patients Diagnosed With Necrotizing Soft Tissue Infections

NCT01417780 is registered in ClinicalTrials.gov with Atox Bio Ltd as lead sponsor.

NCT NCT01417780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01417780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety, Pharmacokinetics and Immunomodulatory Effects of AB103, a CD28 Co-stimulatory Receptor Antagonist, in Patients Diagnosed With Necrotizing Soft Tissue Infections
Lead sponsor
Atox Bio Ltd
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
September 30, 2012
Enrollment
43 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

necrotizing soft tissue infections